Your AI-Trained Oncology Knowledge Connection!

Dwaine Rieves, MD

Articles

Eltrombopag for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura

Andrew Dmytrijuk, MD;Kathy Robie-suh, MD, PhD;Dwaine Rieves, MD;Richard Pazdur, MD

December 1st 2009

On November 20, 2008, the US Food and Drug Administration (FDA) granted accelerated approval for eltrombopag (Promacta Tablets, GlaxoSmithKline) for the treatment of thrombocytopenia in patients with chronic immune thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulin therapy, or splenectomy.

Romiplostim for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura

Faranak Jamali, MD;Steven Lemery, MD;Kassa Ayalew, MD;Suzanne Robottom, MD;Kathy Robie-suh, MD, PhD;Dwaine Rieves, MD;Richard Pazdur, MD

July 14th 2009

On August 22, 2008, the US Food and Drug Administration (FDA) granted marketing approval (licensure) to romiplostim (Nplate, Amgen Inc) for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.

Deferasirox for the Treatment of Chronic Iron Overload in Transfusional Hemosiderosis

George Shashaty, MD;Raymond Frankewich, PhD;Tamal Chakraborti, PhD;Jasti Choudary, PhD;Suliman Al-fayoumi, PhD;Alice Kacuba, RN, MSN;Sonia Castillo, PhD;Kathy Robie-suh, MD, PhD;Dwaine Rieves, MD;Karen Weiss, MD;Richard Pazdur, MD

December 1st 2006

This report describes the Food and Drug Administration's review of data and analyses leading to the approval of the oral iron chelator, deferasirox for the treatment of chronic iron overload due to transfusional hemosiderosis.